文献速递血栓与止血

口服布鲁顿酪氨酸激酶抑制剂阻断血小板Fc受体CD32a(FcγRIIA)活化:肝素诱导性血小板减少症的新选择?

Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?
PubMed 文献 · Blood Adv · 2019-01-01

本研究探讨已上市或在研的布鲁顿酪氨酸激酶抑制剂(BTKi)能否阻断FcγRIIA介导的血小板活化。所有BTKi均抑制抗体交联FcγRIIA或抗CD9抗体诱导的血小板聚集与分泌,并抑制肝素诱导性血小板减少症(HIT)患者血清诱导的聚集;单次口服伊布替尼280 mg即可快速持续抑制FcγRIIA活化,提示值得在HIT患者中验证。

要点

  • 已上市及在研BTKi均能抑制FcγRIIA交联诱导的血小板聚集和分泌。
  • 伊布替尼、阿卡替尼的IC50低于B细胞恶性肿瘤患者血浆药物浓度4–5倍。
  • 单次口服伊布替尼280 mg可快速持续抑制血小板FcγRIIA活化。

核心结论

  • 不可逆和可逆BTKi均能强效抑制血液中FcγRIIA介导的血小板活化,该新思路值得在HIT患者中测试。

研究设计与样本

  • 体外研究:使用已批准(伊布替尼、阿卡替尼)或在研(泽布替尼、tirabrutinib、evobrutinib、fenebrutinib)BTKi,检测抗体交联FcγRIIA或抗CD9抗体刺激后的血小板活化。
  • 另检测BTKi对HIT患者血清刺激的供者血血小板聚集的影响,以及单次口服伊布替尼280 mg的抑制效果。

主要发现

  • 所有BTKi均阻断抗体介导交联FcγRIIA诱导的血小板聚集和分泌,也阻断抗CD9抗体诱导的聚集。
  • FcγRIIA交联诱导血小板聚集的IC50:伊布替尼0.08 µM、泽布替尼0.11 µM、阿卡替尼0.38 µM、tirabrutinib 0.42 µM、evobrutinib 1.13 µM、可逆性fenebrutinib 0.011 µM。
  • 伊布替尼和阿卡替尼的IC50比B细胞恶性肿瘤患者血浆药物浓度低4–5倍。
  • BTKi还抑制FcγRIIA交联后的ATP分泌、P-选择素表达和血小板-中性粒细胞复合物形成。
  • BTKi阻断HIT患者血清刺激的供者血血小板聚集;单次口服伊布替尼280 mg足以快速持续抑制血小板FcγRIIA活化。

临床怎么用

  • BTKi可能作为HIT中靶向FcγRIIA血小板活化通路的潜在治疗选择,但需在HIT患者中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Activation of the platelet Fc-receptor CD32a (FcγRIIA) is an early and crucial step in the pathogenesis of heparin-induced thrombocytopenia type II (HIT) that has not been therapeutically targeted. Downstream FcγRIIA Bruton tyrosine kinase (BTK) is activated; however, its role in Fc receptor-induced platelet activation is unknown. We explored the potential to prevent FcγRIIA-induced platelet activation by BTK inhibitors (BTKi's) approved (ibrutinib, acalabrutinib) or in clinical trials (zanubrutinib [BGB-3111] and tirabrutinib [ONO/GS-4059]) for B-cell malignancies, or in trials for autoimmune diseases (evobrutinib, fenebrutinib [GDC-0853]). We found that all BTKi's blocked platelet activation in blood after FcγRIIA stimulation by antibody-mediated cross-linking (inducing platelet aggregation and secretion) or anti-CD9 antibody (inducing platelet aggregation only). The concentrations that inhibit 50% (IC50) of FcγRIIA cross-linking-induced platelet aggregation were for the irreversible BTKi's ibrutinib 0.08 µM, zanubrutinib 0.11 µM, acalabrutinib 0.38 µM, tirabrutinib 0.42 µM, evobrutinib 1.13 µM, and for the reversible BTKi fenebrutinib 0.011 µM. IC50 values for ibrutinib and acalabrutinib were four- to fivefold lower than the drug plasma concentrations in patients treated for B-cell malignancies. The BTKi's also suppressed adenosine triphosphate secretion, P-selectin expression, and platelet-neutrophil complex formation after FcγRIIA cross-linking. Moreover, platelet aggregation in donor blood stimulated by sera from HIT patients was blocked by BTKi's. A single oral intake of ibrutinib (280 mg) was sufficient for a rapid and sustained suppression of platelet FcγRIIA activation. Platelet aggregation by adenosine 5'-diphosphate, arachidonic acid, or thrombin receptor-activating peptide was not inhibited. Thus, irreversible and reversible BTKi's potently inhibit platelet activation by FcγRIIA in blood. This new rationale deserves testing in patients with HIT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Goldmann L, Duan R, Kragh T, et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT? Blood Adv. 2019. PMID: 31809536. doi:10.1182/bloodadvances.2019000617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。